| scholarly article | Q13442814 |
| P50 | author | Paul A Gurbel | Q89230591 |
| P2093 | author name string | Ashwani K Bassi | |
| Kevin P Bliden | |||
| Udaya S Tantry | |||
| Rolf P Kreutz | |||
| Kirk Guyer | |||
| Kazi A Zaman | |||
| Peter W Cho | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 1820-6 | |
| P577 | publication date | 2005-11-15 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study | |
| P478 | volume | 46 |
| Q46624023 | "Short" thrombelastography as a test of platelet reactivity in response to antiplatelet therapy: validation and reproducibility |
| Q37550156 | A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes |
| Q40329955 | A point-of-care assay to measure platelet aggregation in patients taking clopidogrel |
| Q52675556 | ADP Platelet Hyperreactivity Predicts Cardiovascular Disease in the FHS (Framingham Heart Study). |
| Q36715768 | AZD6140. |
| Q34111144 | Adenosine diphosphate–induced platelet-fibrin clot strength: A new thrombelastographic indicator of long-term poststenting ischemic events |
| Q38958862 | Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors |
| Q40014803 | Antiplatelet Resistance-Does it Exist and How to Measure it? |
| Q37437158 | Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements |
| Q37882712 | Antiplatelet drug therapy: role of pharmacodynamic and genetic testing |
| Q40572790 | Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction. |
| Q37838100 | Antiplatelet therapy and vascular disease: an update. |
| Q45044348 | Antiplatelet therapy: What have we learned from the ANTARCTIC trial? |
| Q40329892 | Antiplatelet therapy: current strategies and future trends |
| Q39667584 | Aspirin and clopidogrel resistance using the cone and plate(let) analyser in Indian patients with coronary artery disease |
| Q28200610 | Aspirin and clopidogrel resistance: consideration and management |
| Q37018788 | Aspirin insensitive thrombophilia: transcript profiling of blood identifies platelet abnormalities and HLA restriction |
| Q38132923 | Assessing post-treatment platelet reactivity: a focus on patient selection and setting. |
| Q37902507 | Assessment of oral antithrombotic therapy by platelet function testing |
| Q53163564 | Association of ABCB1 promoter methylation with aspirin exposure, platelet function, and clinical outcomes in Chinese intracranial artery stenosis patients. |
| Q35921906 | Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting |
| Q91801852 | Association of Thrombelastographic Parameters with Complications in Patients with Intracranial Aneurysm After Stent Placement |
| Q34019082 | Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy |
| Q51369765 | Brachial artery endothelial function predicts platelet function in control subjects and in patients with acute myocardial infarction. |
| Q33637814 | C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting |
| Q36813106 | Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease |
| Q50536660 | Central aortic pulse pressure, thrombogenicity and cardiovascular risk. |
| Q47331979 | Changes in platelet function with inflammation in patients undergoing vascular surgery. |
| Q38099541 | Cigarette smoking and clopidogrel interaction |
| Q91817259 | Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements |
| Q89751378 | Clinical Implications of "Tailored" Antiplatelet Therapy in Patients With Chronic Total Occlusion |
| Q26849254 | Clinical application of cardiovascular pharmacogenetics |
| Q36800844 | Clinical characteristics associated with high on-treatment platelet reactivity of patients undergoing PCI after a 300 mg loading dose of clopidogrel, measured by thrombelastography |
| Q34390050 | Clinical importance of aspirin and clopidogrel resistance |
| Q37841560 | Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention |
| Q34212563 | Clopidogrel "resistance": where are we now? |
| Q38640902 | Clopidogrel Response Variability: Review of the Literature and Practical Considerations |
| Q26823542 | Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? |
| Q57098373 | Clopidogrel discontinuation and platelet reactivity following coronary stenting |
| Q36819608 | Clopidogrel resistance--the cardiologist's perspective |
| Q40347840 | Clopidogrel resistance: fact and fiction |
| Q38274517 | Clopidogrel resistance: the way forward |
| Q43767100 | Clopidogrel responsiveness in patients undergoing peripheral angioplasty. |
| Q36804776 | Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel |
| Q42055431 | Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy? |
| Q37364537 | Contemporary issues on clopidogrel therapy |
| Q37781893 | Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery |
| Q53471405 | Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay. |
| Q45918932 | Correlation of inhibition of platelet aggregation with cardiovascular and bleeding outcomes in acute coronary syndromes. |
| Q37326634 | Current concepts about inhibition of platelet aggregation |
| Q26771106 | Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications |
| Q36433515 | Detailed analysis of periprocedural strokes in patients undergoing intracranial stenting in Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS). |
| Q41848961 | Determinants to optimize response to clopidogrel in acute coronary syndrome |
| Q38936364 | Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system |
| Q42871091 | Determination of the Prevalence of Aspirin and Clopidogrel Resistances in Patients with Coronary Artery Disease by using Various Platelet-function Tests |
| Q39025194 | Does the response to aspirin and clopidogrel vary over 6 months in patients with ischemic heart disease? |
| Q37752222 | Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. |
| Q28198683 | Drug insight: Clopidogrel nonresponsiveness |
| Q34983154 | Drug-drug interaction between clopidogrel and the proton pump inhibitors. |
| Q50980833 | Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience. |
| Q37396871 | Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study |
| Q42167779 | Effect of exercise on platelet activation during aspirin or clopidogrel intake in healthy men. |
| Q35473568 | Effect of gender difference on platelet reactivity |
| Q43265580 | Effects of clopidogrel on "aspirin specific" pathways of platelet inhibition |
| Q45888145 | Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation |
| Q37328353 | Efficacy of Clopidogrel and Clinical Outcome When Clopidogrel Is Coadministered With Atorvastatin and Lansoprazole: A Prospective, Randomized, Controlled Trial |
| Q38243854 | Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures. |
| Q43143208 | Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization |
| Q35208684 | Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). |
| Q28219204 | Evaluation of the TEG platelet mapping assay in blood donors |
| Q28221921 | Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation? |
| Q54546944 | Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance. |
| Q37988850 | Evolving role of platelet function testing in coronary artery interventions |
| Q34969512 | Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease |
| Q55372718 | Fibrin Clot Strength in Patients with Diabetes Mellitus Measured by Thrombelastography. |
| Q88678011 | Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention |
| Q36990172 | Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor |
| Q38799118 | First report of the point-of-care TEG: A technical validation study of the TEG-6S system |
| Q33399119 | Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity |
| Q40372167 | HIV infection, ACS, PCI and high platelet reactivity: ingredients for a perfect thrombotic storm |
| Q38391222 | High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. |
| Q30450312 | High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study |
| Q26824850 | High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance |
| Q34211191 | Hostility and platelet reactivity in individuals without a history of cardiovascular disease events |
| Q43631457 | Hypercoagulability in dogs with protein-losing nephropathy as assessed by thromboelastography. |
| Q44167859 | Hypercoagulability in patients undergoing coronary artery bypass grafting: prevalence, patient characteristics and postoperative outcome. |
| Q44054496 | Hypercoagulability in relation to coronary artery bypass graft patency and clinical outcome |
| Q46472467 | Hypercoagulation assessed by thromboelastography is neither related to infarct size nor to clinical outcome after primary percutaneous coronary intervention |
| Q39672053 | Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hyporesponsiveness |
| Q94526212 | Impact of Routine Platelet Reactivity Testing with VerifyNow Assay on Antiplatelet Choice After Percutaneous Coronary Intervention |
| Q40211125 | Impaired Platelet Aggregation and Rebalanced Hemostasis in Patients with Chronic Hepatitis C Virus Infection |
| Q38637328 | Importance of Endogenous Fibrinolysis in Platelet Thrombus Formation |
| Q38154612 | Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account |
| Q51108799 | Improved predictive value of GRACE risk score combined with platelet reactivity for 1-year cardiovascular risk in patients with acute coronary syndrome who underwent coronary stent implantation. |
| Q57098021 | Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy |
| Q35832159 | Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response |
| Q35070799 | Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients |
| Q33637840 | Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin |
| Q42512335 | Inhibition of platelet aggregation ex vivo is repressed in apolipoprotein E deficient mice. |
| Q45918033 | Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. |
| Q37176153 | Interaction between cigarette smoking and clinical benefit of clopidogrel |
| Q42952510 | Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy |
| Q39021950 | Is arachidonic acid stimulation really a test for the response to aspirin? Time to think again? |
| Q35035904 | Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk? |
| Q38012079 | Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention |
| Q33516375 | Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity |
| Q37608580 | Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence |
| Q38099235 | Monitoring aspirin and clopidogrel response: testing controversies and recommendations |
| Q46789035 | Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting |
| Q35373683 | Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations |
| Q37646648 | Monitoring the hemostasis with rotation thromboelastometry in patients with acute STEMI on dual antiplatelet therapy: First experiences |
| Q90369202 | Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study |
| Q41511099 | P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon? |
| Q58735417 | Parameter Estimation of Platelets Deposition: Approximate Bayesian Computation With High Performance Computing |
| Q38616610 | Peripheral interventions and antiplatelet therapy: Role in current practice |
| Q37642822 | Personalized antiplatelet therapy for coronary artery disease patients: is this the future? |
| Q26775125 | Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls |
| Q42164176 | Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial |
| Q38116753 | Pharmacogenomics of anti-platelet and anti-coagulation therapy |
| Q27022443 | Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? |
| Q30238719 | Pharmacokinetic drug evaluation of vorapaxar for secondary prevention after acute coronary syndrome. |
| Q38154211 | Pharmacology of antiplatelet agents |
| Q33637824 | Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes |
| Q85965701 | Plasma urokinase antigen and C-reactive protein predict angina recurrence after coronary angioplasty |
| Q37678656 | Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions |
| Q36529548 | Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel |
| Q28220600 | Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients |
| Q48162349 | Platelet function monitoring for stent thrombosis in critically III patients with an acute Coronary syndrome. |
| Q34035039 | Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS? |
| Q46358660 | Platelet function profile post-clopidogrel therapy in patients with type 2 diabetes undergoing coronary stent implantation |
| Q38080466 | Platelet function testing in patients with acute coronary syndrome |
| Q36822610 | Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department |
| Q38089082 | Platelet function tests for the monitoring of P2Y12 inhibitors |
| Q44621004 | Platelet function: new drugs, new assays : possible impacts on operative medicine? |
| Q36374945 | Platelet hyperreactivity in response to on- and off-pump coronary artery bypass grafting |
| Q41968141 | Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study |
| Q44479790 | Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target |
| Q57734957 | Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosis |
| Q43077737 | Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy |
| Q41349792 | Point-of-care platelet function testing in patients undergoing PCI: between a rock and a hard place |
| Q44426942 | Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials. |
| Q37693085 | Poor response to clopidogrel: current and future options for its management |
| Q37479088 | Prasugrel for the treatment of patients with acute coronary syndrome |
| Q42931790 | Pre-Procedural Platelet Reactivity After Clopidogrel Loading in Korean Patients Undergoing Scheduled Percutaneous Coronary Intervention |
| Q92433851 | Prediction of Ischemic Events after Percutaneous Coronary Intervention: Thrombelastography Profiles and Factor XIIIa Activity |
| Q46909934 | Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting |
| Q46761762 | Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation |
| Q37662630 | Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response |
| Q34186272 | Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects |
| Q37540088 | Recent developments in clopidogrel pharmacology and their relation to clinical outcomes |
| Q37693951 | Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. |
| Q37039218 | Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients |
| Q90084142 | Residual platelet reactivity is preferred over platelet inhibition rate in monitoring antiplatelet efficacy: insights using thrombelastography |
| Q57764181 | Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel a |
| Q37765291 | Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization |
| Q40689554 | Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results |
| Q40010554 | Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease |
| Q33751272 | Smoking Interaction with Clopidogrel; Another Smoker's Paradox? |
| Q36802971 | State of the art in platelet function testing |
| Q50449062 | Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis. |
| Q51541681 | The Importance of the Mean Platelet Aggregation Degree in Long-term Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation. |
| Q92510068 | The Influence of Inflammation on Fibrinogen Turnover and Redistribution of the Hemostatic Balance to a Prothrombotic State in High On-Treatment Platelet Reactivity-Dual Poor Responder (HTPR-DPR) Patients |
| Q42929936 | The Influence of Proton Pump Inhibitors on the Antiplatelet Potency of Clopidogrel Evaluated by 5 Different Platelet Function Tests |
| Q38988962 | The Potential Value of Near Patient Platelet Function Testing in PCI: Randomised Comparison of 600 mg versus 900 mg Clopidogrel Loading Doses |
| Q37664571 | The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions |
| Q37923969 | The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders |
| Q51806426 | The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. |
| Q37164383 | The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention |
| Q42114136 | The significance of clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the verifynow p(2)y(12) assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation |
| Q37315628 | The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence |
| Q33384385 | The use of thrombelastography to determine coagulation status in severe anorexia nervosa: a case series |
| Q38472522 | Thrombelastographic haemostatic status and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): assessing and monitoring the antithrombotic effect of clopidogrel and aspirin versus aspirin alone in hypercoagulable patients: st |
| Q53450451 | Thrombelastographic hypercoagulability and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): a randomized controlled trial. |
| Q36664802 | Thrombelastography: current clinical applications and its potential role in interventional cardiology |
| Q41968003 | Thrombin induced platelet-fibrin clot strength in relation to platelet volume indices and inflammatory markers in patients with coronary artery disease |
| Q45026344 | Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis. |
| Q43723087 | Thromboelastography defines late hypercoagulability after TBI: a pilot study |
| Q36589808 | Thromboelastography for monitoring platelet function in unruptured intracranial aneurysm patients undergoing stent placement |
| Q28200486 | Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy? |
| Q50118433 | Thromboelastometry and Platelet Function during Acclimatization to High Altitude. |
| Q45072764 | Thromboembolism after WATCHMAN(TM) in a clopidogrel non-responder: A case for concern? |
| Q64983348 | Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. |
| Q37841570 | Ticagrelor: from concept to clinical evaluation |
| Q46934452 | To adjust or not to adjust the platelet count in light transmission aggregometry in patients receiving dual aspirin/clopidogrel treatment |
| Q41817424 | Towards personalized medicine based on platelet function testing for stent thrombosis patients |
| Q26772996 | Type 2 Diabetes and ADP Receptor Blocker Therapy |
| Q48354113 | Use of viscoelastic tests to predict clinical thromboembolic events: A systematic review and meta-analysis. |
| Q37936014 | Variability of clopidogrel response in patients with type 2 diabetes mellitus |
| Q101476302 | Vascular protective effect of aspirin and rivaroxaban upon endothelial denudation of the mouse carotid artery |
Search more.